Social media represent a new way for drug companies to interact with consumers. But transitioning medical communication and marketing campaigns to the internet poses several thorny legal and regulatory issues. Sarah Webb investigates.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fox, S. & Jones S. The Social Life of Health Information. (Pew Research Center, Washington, DC, June 2009).
Gratton, F. A conversation with DDMAC's Dr. Jean-Ah Kang http://fdasm.com/docs/FDA_Ignite_012810_Interview_Transcript.pdf
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Webb, S. Drug marketing and the new media. Nat Biotechnol 28, 396–398 (2010). https://doi.org/10.1038/nbt0510-396
Issue Date:
DOI: https://doi.org/10.1038/nbt0510-396
